Omeros Corp. (OMER)
NASDAQ
Closed
Oct 20, 2026
Day's Range
16.1152 wk Range
6.24Overview - OMER - Omeros Corp.
Key Statistics
Valuation
Enterprise Value
1.34B
P/E (Trailing)
‪13.40‬
P/E (Forward)
‪13.29‬
PEG Ratio
‪-0.09‬
Price / Sales (TTM)
‪30.80‬
Price / Book
‪-22.96‬
EV / EBITDA
‪-18.75‬
Profitability
Gross Margin
‪97.20%‬
Profit Margin
‪324.88%‬
Operating Margin
‪0.25%‬
Return on Assets
‪-18.67%‬
Return on Equity
‪2.76%‬
Ownership
Shares Outstanding
72.08M
Float
69.28M
Short % of Shares Outstanding
‪16.29%‬
Held by Insiders
‪4.08%‬
Held by Institutions
‪51.36%‬
Price stats
Beta
‪2.57‬
50-Day Avg
‪18.29‬
200-Day Avg
‪13.33‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
3 analysts
Shariah Compliance
Report Date: Feb 15, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - OMER - Omeros Corp.
Peers - OMER - Omeros Corp.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- OMERNASDAQOmeros Corp.1.18BMarket Cap+51.87%52-week change13.40P/E (Trailing)‪324.88%‬Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.03BMarket Cap-23.08%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.82BMarket Cap+8.90%52-week change17.26P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - OMER - Omeros Corp.
About
Omeros Corp. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. The company concentrates on immunologic and complement-mediated diseases, along with selected orphan and rare indications affecting inflammation, coagulopathies,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
